Cook, J., Johnson, I., Higgins, A., Sidana, S., Warsame, R., Gonsalves, W., Gertz, M. A., Buadi, F., Lacy, M., Kapoor, P., Dispenzieri, A., Kourelis, T., Dingli, D., Fonder, A., Hayman, S., Hobbs, M., Hwa, Y. L., Kyle, R., Leung, N., Go, R., Rajkumar, V. S., & Kumar, S. (2021). outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma. American journal of hematology, 96(3), 330–337. http://access.bl.uk/ark:/81055/vdc_100121919579.0x00004a